Option for Investors With Sizeable Losses to Lead the Ocugen, Inc. Course Motion Lawsuit
SAN DIEGO, July 02, 2021–(Enterprise WIRE)–Robbins Geller Rudman & Dowd LLP announces purchasers of Ocugen, Inc. (NASDAQ:OCGN) securities between February 2, 2021 and June 10, 2021, inclusive (the “Course Period”) have until August 17, 2021 to search for appointment as lead plaintiff in the Ocugen class motion lawsuit. The scenario is captioned Nicanor v. Ocugen, Inc., No. 21-cv-02725, and is assigned to C. Darnell Jones, II of the Japanese District of Pennsylvania. The Ocugen class action lawsuit expenses Ocugen and sure of its executives with violations of the Securities Exchange Act of 1934.
If you desire to serve as direct plaintiff of the Ocugen class motion lawsuit or have inquiries regarding your legal rights pertaining to the Ocugen class action lawsuit, remember to give your information and facts in this article or get hold of counsel, J.C. Sanchez of Robbins Geller, at 800/449-4900 or 619/231-1058 or by means of e-mail at [email protected]. Guide plaintiff motions for the Ocugen class motion lawsuit should be filed with the courtroom no afterwards than August 17, 2021.
Case ALLEGATIONS: The Ocugen course action lawsuit alleges that, throughout the Course Interval, defendants produced bogus and deceptive statements and unsuccessful to disclose that: (i) the data that Ocugen submitted to the U.S. Foodstuff and Drug Administration (“Fda”) was inadequate to support an Emergency Use Authorization (“EUA”) (ii) Ocugen would not file an EUA with the Fda and (iii) as a end result, Ocugen’s monetary statements, as perfectly as defendants’ statements about Ocugen’s company, functions, and potential clients were being fake and misleading and/or lacked a realistic basis.
On June 10, 2021, Ocugen issued a push release saying that it would go after a biologics license application (“BLA”) with the Food and drug administration alternatively of the formerly announced EUA. In performing so, Ocugen exposed that “[t]he Fda presented feed-back to Ocugen pertaining to the Learn File the Corporation experienced beforehand submitted and recommended that Ocugen pursue a BLA submission rather of an EUA software for its vaccine candidate and asked for added information and facts and data. Ocugen is in conversations with the Fda to realize the added facts demanded to aid a BLA submission. The Firm anticipates that knowledge from an more medical trial will be needed to support the submission.” On this news, the price tag of Ocugen stock fell more than 28%, harming investors.
THE Lead PLAINTIFF Procedure: The Non-public Securities Litigation Reform Act of 1995 permits any trader who purchased Ocugen securities in the course of the Course Time period to look for appointment as lead plaintiff in the Ocugen class action lawsuit. A guide plaintiff is normally the movant with the greatest monetary interest in the aid sought by the putative class who is also common and enough of the putative course. A direct plaintiff acts on behalf of all other class users in directing the Ocugen class action lawsuit. The guide plaintiff can pick out a regulation business of its selection to litigate the Ocugen course motion lawsuit. An investor’s ability to share in any likely foreseeable future restoration of the Ocugen course action lawsuit is not dependent on serving as lead plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 legal professionals in 9 workplaces nationwide, Robbins Geller Rudman & Dowd LLP is the major U.S. legislation agency symbolizing investors in securities class steps. Robbins Geller lawyers have obtained a lot of of the largest shareholder recoveries in heritage, which includes the major securities course action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Course Motion Products and services Leading 50 Report rated Robbins Geller first for recovering $1.6 billion for buyers past calendar year, far more than double the amount recovered by any other securities plaintiffs’ company. Be sure to pay a visit to http://www.rgrdlaw.com for much more data.
Legal professional marketing.
Previous success do not assurance long run outcomes.
Services may well be executed by lawyers in any of our places of work.
Perspective source model on businesswire.com: https://www.businesswire.com/news/residence/20210702005027/en/
Contacts
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101 • 619-231-1058
J.C. Sanchez, 800-449-4900
[email protected]